Neuberger Berman Group LLC Outlook Therapeutics, Inc. Transaction History

Neuberger Berman Group LLC

  • $123 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Nov 14, 2024
BUY
$0.22 - $0.66 $7,341 - $22,024
33,371 New
33,371 $13,000
Q4 2023

Feb 09, 2024
BUY
$0.22 - $0.66 $1,123 - $3,369
5,106 Added 18.06%
33,371 $13,000
Q3 2023

Nov 14, 2023
BUY
$0.2 - $1.78 $5,653 - $50,311
28,265 New
28,265 $6,000

Others Institutions Holding OTLK

# of Institutions
3
Shares Held
31.5K
Call Options Held
0
Put Options Held
0
View Full List

About Outlook Therapeutics, Inc.

OTLK Quotes by TradingView
  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.17B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Neuberger Berman Group LLC Portfolio

Follow Neuberger Berman Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Neuberger Berman Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Neuberger Berman Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email